Leukocyte Imbalances in Mucopolysaccharidoses Patients

Area of Science:

• Immunology
• Genetics
• Biochemistry

Background:

• Mucopolysaccharidoses (MPS) are rare inherited lysosomal storage diseases (LSDs) impacting glycosaminoglycan degradation.
• MPS II results from IDS gene mutations causing iduronate-2-sulfatase deficiency and heparan/dermatan sulfate accumulation.
• MPS VI stems from ARSB gene mutations leading to arylsulfatase B deficiency and dermatan sulfate accumulation.

Purpose of the Study:

• To investigate immune system alterations in patients with Mucopolysaccharidoses type II (MPS II) and type VI (MPS VI).
• To compare leukocyte populations in MPS II and MPS VI patients with healthy controls.
• To identify disease-specific immune cell changes in MPS patients.

Main Methods:

• Analysis of leukocyte populations in patients diagnosed with MPS II and MPS VI.
• Comparison of immune cell percentages (NK, monocytes, T, NKT, B cells) between MPS patients and control groups.
• Assessment of T cell subsets (naïve vs. memory) in MPS patients.

Main Results:

• MPS VI patients showed a decreased percentage of natural killer (NK) cells and monocytes compared to controls.
• No significant alterations in T, invariant NKT, or B cell percentages were observed in either MPS II or MPS VI patients.
• MPS VI patients exhibited a higher frequency of naïve T cells and a lower frequency of memory T cells compared to controls.

Conclusions:

• The study reveals MPS VI-specific alterations in leukocyte populations, including NK cells, monocytes, and T cell subsets.
• These findings suggest that the specific accumulated substrate and enzyme deficiency in MPS VI uniquely impact immune system composition.
• Further research into immune system changes in MPS diseases can inform therapeutic strategies.